Antiplatelet contraindications
Prasugrel: prior TIA or stroke is not a dose-reduction problem
A lower prasugrel dose does not make a prior TIA acceptable under the label. Separate a contraindication from age- and weight-related bleeding cautions before turning a clinical case into tablet arithmetic.
Sources checked October 13, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Read the cerebrovascular history before the dose
The label lists prior TIA or stroke as a contraindication. A transient episode still matters when it was diagnosed as TIA; resolution of symptoms does not erase the history. Active pathological bleeding is another contraindication.
The exam trap is to notice low weight or advanced age first and propose a reduced dose without addressing the prior event. A dose calculation can be perfectly correct while the medicine remains inappropriate.
Do not merge age and history into one rule
Prasugrel is generally not recommended at age 75 or older because of bleeding risk and uncertain benefit, with exceptions described for high-risk situations such as diabetes or prior MI. That wording is not the same as the absolute prior-TIA-or-stroke contraindication.
A learner must preserve the distinction between generally not recommended and contraindicated. The presence of diabetes does not cancel a prior TIA contraindication simply because it can affect the age-related risk-benefit discussion.
Treat low body weight as its own dosing review
For patients below 60 kg, the label advises considering a 5 mg maintenance dose rather than 10 mg. It also notes that effectiveness and safety of the 5 mg dose have not been prospectively studied. This is not permission to reduce any contraindicated prescription until it becomes acceptable.
Weight, age and cerebrovascular history should appear as separate lines in the reasoning. If a case contains more than one concern, name each without making the dose-related one a substitute for medicine selection.
Resolve the plan without causing an unreviewed gap
Patients with PCI and stents can be harmed by premature antiplatelet discontinuation. The label warns of stent thrombosis, MI and death. An unsuitable prasugrel proposal needs an urgent coordinated alternative, not a casual instruction to stop all antiplatelets.
The case assesses whether prasugrel is an appropriate candidate under the stated history. It does not choose the alternative drug or duration for a real patient. Those require the cardiology plan, bleeding risk and other medicines.
A worked case
A fictional post-PCI patient weighs 55 kg and has a documented prior TIA. A draft proposes prasugrel 5 mg daily because the weight is below 60 kg. Does the reduced dose settle suitability?
- Low weight triggers a separate maintenance-dose consideration.
- Prior TIA is a contraindication regardless of that proposed reduction.
- Arrange a coordinated antiplatelet plan rather than approving the smaller dose.
Answer: No. The prior TIA rules out prasugrel under the cited label; dose reduction does not remove it.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does a resolved prior TIA still matter?
Yes. Prior TIA is a contraindication.
2. Does diabetes override that contraindication?
No. Do not confuse an age-related exception with the prior-TIA rule.
3. Does low weight turn a contraindication into a dosing problem?
No.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.